Dihydrotestosterone (DHT) is a biologically active metabolite of the hormone testosterone, formed primarily in the prostate gland, testes, hair follicles, and adrenal glands
A new study has revealed that in addition to testosterone, the masculinization process involves a hormone called androsterone, which originates in other tissues.
In most cases of prostate cancer, tumor cell growth is stimulated by the action of male hormones, or androgens, such as testosterone and dihydrotestosterone.
Maternal obesity and androgen excess induce sex-specific anxiety in the offspring, according to a study on mice by researchers at Karolinska Institutet in Sweden published in The FASEB Journal.
Men with longer exposure to the drugs finasteride and dutasteride had a higher risk of getting persistent erectile dysfunction than men with less exposure, reports a new Northwestern Medicine study.
Research has already shown that taking anabolic steroids is associated with high blood pressure and an increased risk of developing heart conditions such as left ventricular hypertrophy.
Prostate cancer is the second leading cause of mortality among American men with the highest incidence rate of all cancers reported in the U.S. Male sex hormones testosterone (T) and 5α-dihydrotestosterone (5α-DHT) promote prostate cancer progression.
The infant daughters of women with polycystic ovary syndrome (PCOS) show a higher level of an enzyme that activates testosterone and may be an early sign of developing the complex genetic disease, according to a new Northwestern Medicine study.
In older men, decreased sexual activity and desire, not erectile dysfunction, may cause serum testosterone to decline, a new study from Australia finds. The results will be presented Saturday March 7, at ENDO 2015, the annual meeting of the Endocrine Society, in San Diego.
The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Elderly men with low levels of testosterone or other sex hormones have twice the likelihood of having declining physical function over two years' time compared with their peers who have the highest hormone levels, a new study from Australia finds.
Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.
As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).
Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.
Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.
Spanish scientists have confirmed that there is a clear relationship between androgenetic alopecia (common premature baldness) and benign prostate hyperplasia (BPH), a benign enlargement of the prostate that appears in aging men and is associated with certain hormones as dihydrotestosterone. This condition appears in 50% of men over 60 year old and causes voiding syndrome i.e. urinary frequency.
A Kansas State University professor is turning to nutrition to tackle prostate cancer. Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer. Prostate cancer is one of the most common forms of cancer among men in the United States.
A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.
Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.
World renowned hair loss expert, Dr. Larry Shapiro, announced the release of his new book, Fight Hair Loss and Win! and says that Elin Nordegren is not alone when it comes to hair loss as a result of stress. Shapiro says millions of women and men are experiencing the same and that heightened levels of stress, popular nutritional supplements, hormonal imbalances and many other unsuspecting factors are now linked to hair loss.
A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.